Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethazan SCHEMBL49056 | 0.84 | PDE4A (0.73) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL16120984 | 0.83 | ADORA2B (0.81) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| Etamiphyllin SCHEMBL355304 | 0.83 | ADORA2B (0.67) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL18399526 | 0.81 | ADORA2B (0.68) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| Etamiphyllin SCHEMBL1651150 | 0.81 | ADORA2B (0.63) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL16120975 | 0.81 | ADORA2B (0.88) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL16120979 | 0.81 | ADORA2B (0.85) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL11539363 | 0.80 | ADORA2B (0.67) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| Isbufylline SCHEMBL678978 | 0.80 | LMNA (0.78) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL8443037 | 0.79 | ADORA2B (0.77) | ADORA2BLMNAMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ADORA2B 786/4885LMNA 2155/4885MAPT 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.